Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT05035368
Other study ID # LDX0121
Secondary ID
Status Withdrawn
Phase Phase 2
First received
Last updated
Start date September 30, 2021
Est. completion date June 2023

Study information

Verified date January 2022
Source Dompé Farmaceutici S.p.A
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Objectives Primary study objective: To determine whether orally-administered ladarixin versus placebo adjunctive therapy improves insulin sensitivity in overweight, insulin-resistant (IR) type 1 Diabetic (T1D) adult subjects. Secondary study objectives: To determine whether orally-administered ladarixin versus placebo adjunctive therapy is safe and well-tolerated in overweight, IR T1D adult subjects.


Description:

This study is a randomized, placebo-controlled, double-blinded, 2-arm, 2-period crossover phase II trial using the CXCR1/CXCR2 chemokine receptor antagonist ladarixin versus placebo as adjunctive therapy to insulin to improve insulin sensitivity as well as glucometabolic outcomes in adult, insulin-requiring, overweight, IR T1D patients. This trial will randomize 38 male and female patients 21-65 years of age, inclusive, with established insulinrequiring T1D and IR. After a 2:1 randomization into a treatment sequence (either ladarixin followed by placebo, or placebo followed by ladarixin, respectively), patients will be followed up for a maximum of 53 weeks. The study database will be locked when the last patient randomized has completed visit 9 (week 52/53) and data have been cleaned.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date June 2023
Est. primary completion date June 2023
Accepts healthy volunteers No
Gender All
Age group 21 Years to 65 Years
Eligibility Inclusion Criteria: 1. clinical diagnosis of autoimmune T1D as documented by positive T1D diabetes-related autoantibodies [the presence at diagnosis of at least one or more of - Insulin autoantibodies (IAA), Anti-GAD (GAD65), Anti-IA2 (IA2), Zinc Transporter 8 (ZnT8) must be documented from medical records or new laboratory measurement (not including IAA)]; 2. age 21-65 years at the time of consent; 3. T1D duration =>5 years; 4. current insulin standard of care (ISOC), either use of an insulin pump or a stable dose level and dose frequency (i.e. established dose range that does not fluctuate beyond 1SD of the median over a period of the last two months prior to enrollment), multiple daily injections of insulin (at least 3 injections per day) for the last two months prior to enrollment, with no plans to switch the modality of insulin administration during the 4 months following screening (e.g., injection user switching to a pump, pump user switching to injections); 5. HbA1c between 7.5%-10.0%, inclusive, as per results of screening laboratory measurement; 6. evidence of IR based on a total daily insulin dose >0.8 U/kg/ day and/or a screening estimated glucose disposal rate (eGDR) < 9 mg/kg/min 1-3 value strongly indicative of IR, sex- and ageadjusted; 7. subject is overweight or obese with a BMI of between 25-40 kg/m2, inclusive; 8. ability to comply with all protocol procedures for the duration of the study, including scheduled follow-up visits and examinations, and willing to be contacted by clinical trial staff; 9. provision of written informed consent prior of any study-related procedure not part of standard medical care. Exclusion Criteria: 1. patients with known or suspected hypersensitivity to non-steroidal anti-inflammatory drugs or any excipient of the investigational medicinal products (e.g. lactose and croscarmellose) as well as patients with congenital lactase deficiency, galactosaemia or glucose-galactose intolerance will have to be excluded; 2. use of non-insulin medications for adjunctive blood glucose control (e.g: antidiabetic agents such as metformin, sulfonylureas, glinides, thiazolidinediones, exenatide, liraglutide, DPP-IV inhibitors, SGLT-2 inhibitors or amylin); 3. use of medications for weight reduction (such as: Belviq (lorcaserin), Qsymia (Phentermine + topiramate), Orlistat (xenical)); 4. use of a medication such as stimulants, antidepressants and/or psychotropic agents that could affect weight gain or glycemic control of T1D; 5. subject is on treatment with drugs metabolized by CYP2C9 with a narrow therapeutic index [i.e., phenytoin, warfarin, and high dose of amitriptyline (>50 mg/day)]; 6. any medications known to influence glucose tolerance (e.g. beta-blockers, angiotensin-converting enzyme inhibitors, interferons, quinidine antimalarial drugs, lithium, niacin, etc.); 7. evidence of cardiac QTcF > 470 msec and/or any history of significant cardiovascular disease/abnormality; 8. any condition, including unstable dietary approach and disordered eating behaviour patterns, that in the judgment of the investigator will adversely affect patient's safety or the completion of the protocol or otherwise confound study outcome; 9. pregnancy (females) based on serum test (quantitative beta hCG) at screening; unwillingness to use effective contraceptive measures up to 2 months following trial discharge (females and males);effective contraceptive measures include a hormonal birth control (e.g. oral pills, long term injections, vaginal ring, patch); the intrauterine device (IUD); a double barrier method (e.g. condom or diaphragm plus spermicide foam). 10. clinical diagnosis of celiac disease that is in poor control as defined by most recent tissue transglutaminase (tTG) that is in the abnormal range; 11. history of =1 Diabetic Ketoacidosis (DKA) events in the past 6 months; 12. history of =1 severe hypoglycemic events (cognitive impairment that required assistance to treat) in the past 6 months; 13. hypoalbuminemia defined as serum albumin < 3 g/dL ; 14. hepatic dysfunction defined by increased ALT/AST > 3 x upper limit of normal (ULN) and increased total bilirubin > 3 mg/dL [>51.3 µmol/L]; 15. moderate to severe renal impairment calculated by estimated Glomerular Filtration Rate (eGFR) <60 mL/min/1.73 m2 as determined using Chronic Kidney Disease Epidemiology Collaboration (CKDEPI) creatinine equation; 16. poor accessibility to veins for blood collection; 17. past (within 1 month prior to randomization) or current administration of any immunosuppressive medications (including oral, inhaled or systemically injected steroids) and use of any investigational agents, including any agents that impact the immune response or the cytokine system; 18. condition which interferes with the ability to accurately determine glycated HbA1c. Examples include: Genetic variants (e.g. HbS trait, HbC trait), elevated fetal hemoglobin (HbF) and chemically modified derivatives of hemoglobin (e.g. carbamylated Hb in patients with renal failure); Any condition that shortens erythrocyte survival or decreases mean erythrocyte age (e.g., recovery from acute blood loss, hemolytic anemia); Iron deficiency anemia, iron replacement therapy; 19. significant systemic infection during the 4 weeks before the first dose of study drug (e.g., infection requiring hospitalization, major surgery, or i.v. antibiotics to resolve; other infections, e.g., bronchitis, sinusitis, localized cellulitis, candidiasis, or urinary tract infections, must be assessed on a case-bycase basis by the investigator regarding whether they are serious enough to warrant exclusion).

Study Design


Intervention

Drug:
Ladarixin
Ladarixin will be administered orally at the dose of 400 mg twice a day at about 12-hour interval (morning and evening).
Other:
Placebo
Placebo is administered with the same schedule of Ladarixin.

Locations

Country Name City State
United States Institute of Cellular Therapeutics Allegheny Health Network Pittsburgh Pennsylvania

Sponsors (1)

Lead Sponsor Collaborator
Dompé Farmaceutici S.p.A

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary The mean difference in glucose infusion rate (GIR) from baseline The glucose infusion rate (GIR) is a measure of the rate at which the patient receives intravenous administration of dextrose, which increases blood sugar levels. GIR is expressed in mg per kilogram body weight per minute (mg/Kg/min). Week 25 of each treatment period (visits 4 and 8)
Secondary Change from baseline of HbA1c levels In this study glycated hemoglobin (HbA1c) must be between 7.5%-10.0%, inclusive, as per results of screening laboratory measurement. Week 25/26 (no later than 10 days after the last IMP dose) of each treatment period (visits 5 and 9)
Secondary Change in average (previous 3 days) daily insulin requirements In this study insulin requirement is calculated as IU/kg/day averaged over the previous 3 days. Week 25/26 (no later than 10 days after the last IMP dose) of each treatment period (visits 5 and 9)
See also
  Status Clinical Trial Phase
Completed NCT05160142 - Diabetes Inspired Culinary Education Early Phase 1
Completed NCT01928329 - A Phase II Trial to Examine the Effect of Subcutaneous Exenatide (Bydureon®) on Glucose Control in Patients With Type I Diabetes Phase 2
Completed NCT02127762 - The Effect of Mindfulness Based Stress Reduction in Patients With Painful Diabetic Peripheral Neuropathy N/A
Completed NCT00999375 - Cultivating Healthy Environments in Families With Type 1 Diabetes (CHEF) Phase 2
Completed NCT04279613 - A Multiple Ascending Dose Trial Investigating Safety, Tolerability and Pharmacokinetics of NNC0361-0041 Phase 1
Not yet recruiting NCT02117518 - Selective Immunotargeting of Pathogenic CD8 T Cells of Type 1 Diabetes Patients N/A
Withdrawn NCT01477476 - Anti-IL-1 Treatment in Children Diabetic Keto-Acidosis (DKA) at Diagnosis of Type 1 Diabetes Phase 2
Terminated NCT01308437 - Immunosafety Study of Recombinant Human Insulins in Type 1 Diabetics Phase 3
Terminated NCT01652911 - A Phase I/II Study of the Safety and Efficacy of Sernova's Cell PouchTM for Therapeutic Islet Transplantation Phase 1/Phase 2
Completed NCT06242548 - How Type I Diabetes Responds to Different Diets (Normoglucidic or Ketogenic) During Physical Activity at Altitude N/A
Completed NCT00351650 - Assessment of Beta Cell Mass in Type 1 Diabetes With 11C-Dihydrotetrabenazine and PET Scan N/A
Withdrawn NCT00361608 - Monitoring of Nocturnal Hypoglycemia Using EarlySense Monitoring Device N/A
Terminated NCT03653533 - Evaluation of the Function "Stop Before Hypoglycemia" on External Insulin Pump N/A
Completed NCT00340639 - Management of Type 1 Diabetes Among Adolescents N/A
Completed NCT02634216 - Effects of Capros in Patients With Type-1 Diabetes N/A
Completed NCT02002130 - The Use of Glutamic Acid Decarboxylase (GAD) and Gamma-Amino Butyric Acid (GABA) in the Treatment of Type I Diabetes Phase 1
Withdrawn NCT01623388 - Epigenetic Modifications of Diabetes Mellitus Type I N/A
Completed NCT02612493 - Obesity and Metabolic Surgery in Patients With Type I Diabetes N/A
Completed NCT01843114 - Measurement of Total Retinal Blood Flow in Patients With Diabetes and Healthy Subjects N/A
Withdrawn NCT01398670 - Immunogenicity Study of Wockhardt's Insulin Lispro/Lispro Mix Basal Bolus Regimen in Type 1 Diabetics Phase 3